Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 32 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016', provides an overview of the Fibrinogen Deficiency (Factor I Deficiency) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fibrinogen Deficiency (Factor I Deficiency)
- The report reviews pipeline therapeutics for Fibrinogen Deficiency (Factor I Deficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Fibrinogen Deficiency (Factor I Deficiency) therapeutics and enlists all their major and minor projects
- The report assesses Fibrinogen Deficiency (Factor I Deficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Fibrinogen Deficiency (Factor I Deficiency)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fibrinogen Deficiency (Factor I Deficiency) Overview 6
Therapeutics Development 7
Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Overview 7
Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Development by Companies 8
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Fibrinogen Deficiency (Factor I Deficiency) - Products under Development by Companies 11
Fibrinogen Deficiency (Factor I Deficiency) - Companies Involved in Therapeutics Development 12
Biotest AG 12
China Biologic Products, Inc. 13
Grifols, S.A. 14
LFB S.A. 15
Octapharma AG 16
Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 23
fibrinogen (human) - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
fibrinogen concentrate (human) - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
fibrinogen concentrate (human) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
fibrinogen concentrate (human) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
fibrinogen concentrate (human) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Fibrinogen Deficiency (Factor I Deficiency) - Dormant Projects 28
Fibrinogen Deficiency (Factor I Deficiency) - Discontinued Products 29
Fibrinogen Deficiency (Factor I Deficiency) - Product Development Milestones 30
Featured News & Press Releases 30
Mar 23, 2012: China Biologic Receives SFDA Approval To Begin Clinical Trials For Human Fibrinogen 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 31
Disclaimer 32

List of Tables

Number of Products under Development for Fibrinogen Deficiency (Factor I Deficiency), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Biotest AG, H2 2016 12
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by China Biologic Products, Inc., H2 2016 13
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Grifols, S.A., H2 2016 14
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by LFB S.A., H2 2016 15
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Octapharma AG, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 22
Fibrinogen Deficiency (Factor I Deficiency) - Dormant Projects, H2 2016 28
Fibrinogen Deficiency (Factor I Deficiency) - Discontinued Products, H2 2016 29